

Mylan Laboratories

[View the current Mylan Laboratories Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/7312-Mylan+Laboratories.html)

(<http://www.bioportfolio.com/biocorporate/7312-Mylan+Laboratories.html>)

Contact Details:

1500 Corporate Drive Suite 400

Canonsburg

PA

15317

United States of America

Tel: 724-514-1800

Fax:

Email: investor_relations@mylan.com

Mylan is a global pharmaceutical company with market leading positions in generic pharmaceuticals, transdermal technology and unit dose packaged products. We focus on providing an extensive line of affordable, high quality prescription drugs in traditional and innovative dosage forms, and we enjoy a well-deserved reputation for scientific expertise in creating difficult-to-formulate and high-barrier-to-entry generic products. Mylan operates three principal subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories Inc. (all wholly-owned), and has a 71.5% controlling interest in Matrix Laboratories Limited (71.5% owned). Mylan Pharmaceuticals Inc., with locations in Morgantown, W.Va., Caguas, Puerto Rico, and Greensboro, N.C., is a world leader in the research, development, production and marketing of generic pharmaceuticals. Mylan Technologies Inc., located in St. Albans and Swanton, Vt., is a leader in transdermal drug delivery technology and is the largest producer of generic and branded transdermal patches for the U.S. market. UDL Laboratories Inc., with locations in Rockford, Ill., and Sugar Land, Texas, is the top U.S.-supplier of unit dose pharmaceuticals to hospitals and other institutions. Mylan also owns a controlling interest in India-based Matrix Laboratories Limited, which provides Mylan with a platform for global expansion and growth. Matrix is the second largest supplier of active pharmaceutical ingredient (API) sourcing and provides expanded marketing capabilities through Docpharma, a Matrix subsidiary that is a primary marketer of branded generics in Europe. Matrix is a public limited company listed on the Bombay Stock Exchange and the National Stock Exchange of India and currently owns, in whole or in part, 12 other facilities and business units located in India, China and South Africa.

BioNews Results for Mylan Laboratories



- [Mylan's Alphapharm victorious in Razadyne patent challenge](#)
News-Medical.Net: Aug 31 2008 9:54AM Matching: mylan laboratories
- [Mylan's Alphapharm Victorious in Patent Challenge on First-to-File Opportunity Razadyne\(R\) Tablets](#)
PR Newswire via Yahoo!: Aug 29 2008 11:44AM Matching: mylan laboratories

- [Mylan's Alphapharm Victorious in Patent Challenge on First-to-File Opportunity Razadyne\(R\) Tablets](#)
Stockwatch: Aug 29 2008 11:40AM Matching: mylan laboratories
- [Mylan's Alphapharm Victorious in Patent Challenge on First-to-File Opportunity Razadyne\(R\) Tablets](#)
Atlanta Business Chronicle: Aug 29 2008 11:51AM Matching: mylan laboratories
- [Mylan's Alphapharm Victorious in Patent Challenge on First-to-File Opportunity Razadyne\(R\) Tablets](#)
San Antonio Business Journal: Aug 29 2008 11:51AM Matching: mylan laboratories
- [Mylan's Alphapharm Victorious in Patent Challenge on First-to-File Opportunity Razadyne\(R\) Tablets](#)
Cincinnati Business Journal: Aug 29 2008 11:48AM Matching: mylan laboratories
- [Mylan's Alphapharm Victorious in Patent Challenge on First-to-File Opportunity Razadyne\(R\) Tablets](#)
The Business Journal Phoenix: Aug 29 2008 11:46AM Matching: mylan laboratories
- [Mylan's Alphapharm Victorious in Patent Challenge on First-to-File Opportunity Razadyne\(R\) Tablets](#)
Nashville Business Journal: Aug 29 2008 11:46AM Matching: mylan laboratories
- [Mylan's Alphapharm Victorious in Patent Challenge on First-to-File Opportunity Razadyne\(R\) Tablets](#)
Columbus Business First: Aug 29 2008 11:44AM Matching: mylan laboratories
- [Mylan's Alphapharm Victorious in Patent Challenge on First-to-File Opportunity Razadyne\(R\) Tablets](#)
San Francisco Business Times: Aug 29 2008 11:43AM Matching: mylan laboratories
- [Mylan's Alphapharm Victorious in Patent Challenge on First-to-File Opportunity Razadyne\(R\) Tablets](#)
Portland Business Journal: Aug 29 2008 11:40AM Matching: mylan laboratories
- [Mylan's Alphapharm Victorious in Patent Challenge on First-to-File Opportunity Razadyne\(R\) Tablets](#)
Breitbart.com: Aug 29 2008 12:07PM Matching: mylan laboratories
- [Mylan's Alphapharm Victorious in Patent Challenge on First-to-File Opportunity Razadyne\(R\) Tablets](#)
Forbes.com: Aug 29 2008 12:06PM Matching: mylan laboratories
- [Mylan's Alphapharm Victorious in Patent Challenge on First-to-File Opportunity Razadyne\(R\) Tablets](#)
Macro World Investor: Aug 29 2008 11:55AM Matching: mylan laboratories
- [Mylan's Alphapharm Victorious in Patent Challenge on First-to-File Opportunity Razadyne\(R\) Tablets](#)
Street Insider: Aug 29 2008 11:44AM Matching: mylan laboratories

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's relate service indepth.

The annual cost is \$495.00 for established organizations and \$295.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.

